UNSPSC 51191507: Spironolactone

This classification denotes a potassium-sparing diuretic with the molecular formula C24H32O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27O7W4T232, chemically known as pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, .gamma.-lactone, (7.alpha.,17.alpha.)- but generally known as spironolactone, which bears US NIH Compound Identifier 5267. European Medicines Agency schedules Spironolactone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10631MIG.

UNSPSC 51191507 Spironolactone is a Commodity code representing individual pharmaceutical products procured by state and local governments for clinical and operational use. Recent state and local solicitations under this code show a divergence between the code's nominal scope and actual buying activity: while the code nominally identifies a specific diuretic medication (spironolactone), the most recent opportunities tagged to it involve broader pharmaceutical supply frameworks and chemical commodities outside the spironolactone product line itself. The City of Meriden's July 2026 IFB for sodium bisulfite chemical supply to its Water Pollution Control Facility and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) January 2026 RFP for generic multi-source pharmaceuticals and over-the-counter products represent the tagged opportunities, though neither directly solicits spironolactone itself. The MMCAP vehicle serves multiple state and local government facilities across participating jurisdictions including Oregon, suggesting that cooperative purchasing arrangements dominate the broader pharmaceutical procurement landscape for state and local buyers, but the code shows limited recent activity specifically tied to spironolactone procurement.

Geographic activity concentrates in Minnesota (through MMCAP's statewide and multi-state cooperative) and Connecticut (City of Meriden), with MMCAP's multi-state framework extending procurement eligibility to at least Oregon. The MMCAP RFP due March 26, 2026 represents the most substantial recent opportunity, structured around established pharmaceutical wholesaler networks (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with evaluation weighted heavily toward price competitiveness (75 percent) and contract terms effective July 1, 2026. The Meriden sodium bisulfite IFB due July 29, 2026 demonstrates municipal procurement of chemicals for water infrastructure but falls outside the pharmaceutical scope the code nominally represents. Spironolactone-specific procurement activity does not appear in the recent opportunity block, indicating limited current demand visibility under this Commodity code.